Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Chimeric Therapeutics Limited has reported a change in the indirect interest of Director Paul Hopper, with a disposal of 2,941,176 CHMO options due to expiration on March 31, 2024. This leaves Hopper with a direct interest of 1,232,142 shares and an indirect interest of 93,762,432 shares, without any remaining options. The update, provided to the ASX under listing rule 3.19A.2, reflects no direct changes in Hopper’s securities and no involvement in contracts that affect his notifiable interest.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.
